paclitaxel
information and resources from the National Cancer Institute
NCI Thesaurus | paclitaxel
A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2). NCI Thesaurus | paclitaxel
A compound extracted from the Pacific yew tree Taxus brevifolia with antineoplastic activity. Paclitaxel binds to tubulin and inhibits the disassembly of microtubules, thereby resulting in the inhibition of cell division. This agent also induces apoptosis by binding to and blocking the function of the apoptosis inhibitor protein Bcl-2 (B-cell Leukemia 2).
Taxol
First line ovarian cancer with 3 hour infusion.
Bristol-Myers Squibb Jun 20 2000
Taxol
For first-line therapy for the treatment of advanced carcinoma of the ovary in combination with cisplatin.
Bristol-Myers Squibb Apr 09 1998
Taxol
For the adjuvant treatment of node-positive breast cancer administered sequentially to standard doxorubicin-containing combination therapy.
Bristol-Myers Squibb Oct 25 1999
Taxol
for use in combination with cisplatin, for the first-line treatment of non-small cell lung cancer in patients who are not candidates for potentially curative surgery and/or radiation therapy.
Bristol-Myers Squibb Jun 30 1998
Taxol
New dosing regimen for patients who have failed initial or subsequent chemotherapy for metastatic carcinoma of the ovary
Bristol-Myers Squibb Jun 22 1994
Taxol
second line therapy for AIDS related Kaposi's sarcoma.
Bristol-Myers Squibb Aug 04 1997
Paxene
treatment of advanced AIDS-related Kaposi's sarcoma after failure of first line or subsequent systemic chemotherapy
Baker Norton Pharmaceuticals, Inc Dec 24 1997
Taxol
Treatment of breast cancer after failure of combination chemotherapy for metastatic disease or relapse within 6 months of adjuvant chemotherapy. Prior therapy should have included an anthracycline unless clinically contraindicated.
Bristol-Myers Squibb Apr 13 1994
Taxol
Treatment of patients with metastatic carcinoma of the ovary after failure of first-line or subsequent chemotherapy.
Bristol-Myers Squibb Dec 29 1992
|
|
|
|
news articles
Subscribe to Opto Circuits FPO for 1-2 yrs: India Infoline 01 Apr 2006
Moneycontrol.com, FY08. EuroCOR recently received CE (European Conformity) mark approval for its TAXCOR Paclitaxel eluting coronary stent system. ...
Blue Membranes Approaches the US and Japan markets 01 Apr 2006
Yahoo! News (press release) This collaboration resulted in the development of a paclitaxel-eluting cobalt chromium coronary stent with a carbon-based nano-composite coating that is ...
Paclitaxel combined with bevacizumab prolongs progression free ... Mar 23, 2006
Innovations-Report, ...randomised clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin) in combination with paclitaxel (Taxol) survived ...
Paclitaxel-Releasing Stent More Effective Than Intra-Coronary ... Mar 17, 2006
DG News CHICAGO, IL -- MARCH 17, 2006 -- Insertion of stents that release the drug paclitaxel to treat stenosis within an implanted bare-metal stent in a coronary ...
Paclitaxel-Bevacizumab Combination Prolongs Progression-Free ... Mar 23, 2006
DG News ...with advanced breast cancer have a significantly longer progression-free survival when bevacizumab (Avastin) is added to their paclitaxel (Taxol), according to ...
ACC Data Show Numerical Trend Favoring TAXUS(R) Coronary Stent ... Mar 29, 2006
PR Newswire (press release), ...clinical trials and registries offered data that indicated a positive numerical trend in the performance of the TAXUS(R) Express2(TM) paclitaxel-eluting stent ...
Paclitaxel Combined With Bevacizumab Prolongs Progression Free ... Mar 25, 2006
Medical News Today (press release), ...clinical trial for patients with breast cancer show that those who received bevacizumab (Avastin®) in combination with paclitaxel (Taxol®) survived without ...
Stents that release the drug paclitaxel to treat stenosis more ... Mar 13, 2006
News-Medical.net, Insertion of stents that release the drug paclitaxel to treat stenosis within an implanted bare-metal stent in a coronary artery reduces the risk of subsequent ...
Paclitaxel-Eluting Stents Top Angioplasty for Preventing ... Mar 13, 2006
DG News ATLANTA, GA -- March 13, 2006 -- The treatment of bare-metal in-stent restenotic lesions with paclitaxel-eluting stents instead of angioplasty followed by ...
CORRECTING and REPLACING Sonus Pharmaceuticals Highlights 2005 ... Mar 16, 2006
International News Service, The discussion will include an overview of the progress to date and future plans for TOCOSOL Paclitaxel, the Company's lead anti-cancer product candidate. ...
Boston Scientific Reveals TAXUS Receives Favorable ACC Data With ... Mar 29, 2006
Trading Markets, ...offered data that indicated a positive numerical trend in the performance of the TAXUS® Express2(TM | charts | news | Powerrating) paclitaxel-eluting stent ...
Gemzar®/Paraplatin® Followed by Taxol®/Paraplatin® as Initial ... Mar 28, 2006
Cancer Consultants (press release), Oncology, the chemotherapy regimen consisting of Gemzar® (gemcitabine) plus Paraplatin® (carboplatin) followed by Taxol® (paclitaxel) plus Paraplatin ...
Shareholders approve acquisition of Guidant Mar 31, 2006
Pioneer Press, ...tissue in the stent. Boston Scientific's Taxus stent uses a different drug, paclitaxel, to achieve the same goal. Abbott would own ...
Gemzar®/Platinol® Superior to VePesid®/Platinol® in Non-Small ... Mar 29, 2006
Cancer Consultants (press release), Paclitaxel plus carboplatin is one of the most commonly used chemotherapy regimens in the treatment of NSCLC in the US and Europe. ...
CytImmune Sciences Receives Phase I SBIR Grant for Next-Generation ... Mar 30, 2006
PharmaLive.com (press release), The first of these new combination drugs, termed CYT-21001, will consist of TNF and a thiolated paclitaxel analog bound to the surface of 27 nm pegylated ...
Sonus Pharmaceuticals to Present at WBBA Invest Northwest(TM) ... Mar 16, 2006
International News Service, The Company's lead oncology product candidate is TOCOSOL(R) Paclitaxel, a new formulation of the widely prescribed anti-cancer drug paclitaxel. ...
Angiotech Pharma Says Trials Reveal Positive Numerical Trend Of ... Mar 29, 2006
Trading Markets, ...several clinical trials and registries offered data that indicated a positive numerical trend in the performance of the TAXUS Express2 paclitaxel-eluting stent ...
SD Pharmaceuticals Inc. Reports Positive Efficacy Data on Its Non ... Mar 24, 2006
Genetic Engineering News, SD Pharmaceuticals Inc. (SDP) today announced that it has completed a battery of pre-clinical studies on its novel nano-emulsion formulation of paclitaxel. ...
Sonus Pharmaceuticals to Release Fourth Quarter and Full Year 2005 ... Mar 2, 2006
Genetic Engineering News, 4:30 PM EST, management will host a conference call to provide a company update, including a review of the progress with TOCOSOL(R) Paclitaxel, the Company's ...
Addition of Ellence® to Standard Chemotherapy Does Not Improve ... Mar 2, 2006
Cancer Consultants (press release), ...addition of the chemotherapy agent Ellence® (epirubicin) to the standard chemotherapy regimen of Paraplatin® (carboplatin) and Taxol® (paclitaxel) does not ...
Angiotech Pharmaceuticals, Inc. announces results for the quarter ... Mar 2, 2006
CNW Telbec (Communiqués de presse), ...fully taxable in 2005, an increase in certain litigation expenditures and a decrease in royalty revenue derived from the sale of paclitaxel-eluting coronary ...
Sonus Pharma hits new 52-week high Mar 17, 2006
BusinessWeek Sonus booked revenue of $8.3 million for the fourth quarter and the year, solely from development revenue for cancer drug Tocosol Paclitaxel from marketing ...
Sonus Pharmaceuticals Narrows Loss in the Fourth Quarter Mar 16, 2006
Canadian Business, The company's revenue stems from its agreement with drug maker Schering AG regarding Sonus' development and testing of Tocosol Paclitaxel, a treatment for ...
Sonus Pharma Q4 Net Loss Narrows On Research Funding - Update Mar 16, 2006
Trading Markets, ...in the fourth quarter, $7.1 million was related to research and development funding for work completed on the Phase 3 trial for TOCOSOL Paclitaxel and related ...
Bayer receives Swiss approval for advanced kidney cancer drug ... Mar 29, 2006
Forbes Bayer recently initiated phase III trials of the drug to treat non-small cell lung cancer in combination with chemotherapeutic agents carboplatin and paclitaxel ...
Pro-Pharmaceuticals Completes Patient Enrollment in Stage 1 of ... Mar 30, 2006
Genetic Engineering News, ...studies with its lead product candidate, DAVANAT(R), in combination with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and ...
Boston Scientific: TAXUS Stent Shows Positive Results In Complex ... Mar 29, 2006
Trading Markets, The STENT Registry showed nine-month results from 5,566 patients who received either a TAXUS Express2 paclitaxel-eluting coronary stent system or a Cypher ...
ArQule to Present Phase 1 Monotherapy Data with ARQ 501 at AACR ... Mar 30, 2006
Genetic Engineering News, ...trials in leiomyosarcoma and head and neck cancer, as well as combination therapy trials with gemcitabine in pancreatic cancer and with paclitaxel in ovarian ...
Opponents help one another after accident Mar 28, 2006
Central Michigan Life, ...news-medical.net. Taxol is known as “paclitaxel� and is a top-selling drug used to fight ovarian and breast cancers. It can ...
Yale Researchers Find Phenoxodiol Restores Sensitivity to ... Mar 29, 2006
DG News ...to overcome this chemical resistance within tumor cells, thereby allowing standard anti-cancer drugs such as cisplatin, carboplatin and paclitaxel to continue ...
Angiotech Pharma Says Data Indicate Numerical Trend Favoring TAXUS ... Mar 29, 2006
Trading Markets, ...said Wednesday that results from studies showed a positive numerical trend in the performance of Boston Scientific's TAXUS Express2 paclitaxel-eluting stent ...
Medtronic Sues Guidant in Ireland Mar 29, 2006
ag-IP-news Agency, Medtronic filed suit in the US District Court for the Eastern District of Texas against Boston Scientific, alleging that the TAXUS Paclitaxel-eluting coronary ...
New Drugs Added to Breast Cancer Guidelines: Presented at NCCN Mar 13, 2006
DG News ...by the National Comprehensive Cancer Network include numerous changes, including the addition of two new drugs -- bevacizumab and albumin-bound paclitaxel. ...
OXiGENE Completes Patient Enrollment in a Phase II Clinical Trial ... Mar 23, 2006
Business Wire (press release), ...triple combination of Combretastatin A4P (CA4P)--OXiGENE's lead therapeutic candidate--together with widely-used chemotherapy agents, carboplatin and paclitaxel ...
Stent Registry Safety Data Favors Taxus® Over Cypher® In The ... Mar 18, 2006
Medical News Today (press release), ...study included follow-up on 5,566 patients at eight coronary centers in the United States who received either a TAXUS® Express2™ paclitaxel-eluting coronary ...
Sonus Pharmaceuticals to Present at Cowen & Co. 26th Annual Health ... Mar 2, 2006
PharmaLive.com (press release), The Company's lead oncology product candidate is TOCOSOL(R) Paclitaxel, a new formulation of the widely prescribed anti-cancer drug paclitaxel. ...
Researchers find environmentally friendly ways to produce more ... Mar 29, 2006
Checkbiotech.org (press release), ...potent versions of Taxol.". Taxol - generically known as paclitaxel - is a top-selling cancer-fighting drug. It's most commonly used ...
Diatos Announces Expansion of Medarex Cancer Product Licensing ... Mar 28, 2006
PR Newswire (press release), The company's therapeutic candidates DTS-301, a novel paclitaxel formulation and DTS-201, a doxorubicin prodrug, respectively entered Phase II and Phase I ...
Sonus to begin testing its second cancer drug Mar 17, 2006
The Herald, Tocosol paclitaxel, a chemotherapy drug, is being tested on about 800 breast cancer patients around the globe in a trial that should be finished this year. ...
Study Finds Shifts In Treatment Trends Prior To Publication Of ... Mar 17, 2006
Medical News Today (press release), Results from the Cancer and Leukemia Group B (CALGB) Study 9344 suggested that adjuvant treatment with the taxane drug paclitaxel is associated with improved ...
Comparison of Drug-Releasing Coronary Stents Show Similar ... Mar 2, 2006
DG News CHICAGO, IL -- March 2, 2006 -- Use of coronary stents that release the drugs sirolimus or paclitaxel produced similar results in patients with new coronary ...
Taxus Stents Superior to Brachytherapy in the Treatment if in ... Mar 15, 2006
DG News ...the American Medical Association (JAMA) on the Taxus V ISR (in-stent restenosis) clinical trial that found the Taxus(R) Express2(TM) paclitaxel-eluting stent ...
Angiotech And Boson Say JAMA Article States TAXUS Stents Superior ... Mar 15, 2006
Trading Markets, ...the Journal of the American Medical Association on the TAXUS V ISR clinical trial that demonstrated the efficacy of the TAXUS Express2 paclitaxel-eluting stent ...
JAMA article says TAXUS(R) stents superior to brachytherapy in the ... Mar 15, 2006
Yahoo! News (press release) ...of the American Medical Association (JAMA) on the TAXUS V ISR (in-stent restenosis) clinical trial that found the TAXUS® Express2(TM) paclitaxel-eluting stent ...
Brachytherapy for In-Stent Restenosis A Distant Second Choice to ... Mar 12, 2006
Journal of American Medical Association (subscription), In this issue of JAMA, Stone et al 17 and Holmes et al 18 report randomized comparisons of vascular brachytherapy vs a paclitaxel-eluting stent and a sirolimus ...
Drug-eluting stents best treatment for managing coronary ... Mar 13, 2006
News-Medical.net, About half of the patients received paclitaxel-eluting stents, while the other half received vascular brachytherapy, which delivers radiation to the inside of ...
Drug that opens a new front in the battle against breast cancer Mar 22, 2006
Times Online, The chemotherapy treatment, paclitaxel, attacks the tumour while Avastin interferes with the formation of blood vessels that starve it of nutrients. ...
STENT registry safety data favors TAXUS(R) over Cypher(R) in the ... Mar 12, 2006
MoneySense.ca (press release), ...included follow-up on 5,566 patients at eight coronary centers in the United States who received either a TAXUS(R) Express2(TM) paclitaxel-eluting coronary ...
Neoadjuvant Aromatase Inhibitors May Be as Effective as ... Mar 27, 2006
DG News In the chemotherapy group, 118 patients received 60 mg/m 2 of doxorubicin and 200 mg/m 2 of paclitaxel every 3 weeks for 4 cycles. ...
Abraxis Oncology Names Joseph Hogan Vice President of US Sales and ... Mar 20, 2006
Finanzen.net, Hogan will be responsible forleading the US sales and marketing teams for ABRAXANE(R) forInjectable Suspension (paclitaxel protein-bound particles ...
NYCOMED ASA Mar 27, 2006
Norway.org, ...of Health. Paclitaxel: A chemo-therapeutic agent, this is effective against certain types of breast and ovarian cancers. TachoComb ...
Boston Scientific to Release Broad Range of Clinical Study Results ... Mar 7, 2006
Finanzen.net, ..."The data we will present at ACC from our TAXUS clinical studies demonstrates the performance of the TAXUS Express2 paclitaxel-eluting stent system as an ...
International Approvals: Ionsys, CoStar, AutoXpress Mar 7, 2006
Medscape (subscription) ...approved a fentanyl HCl iontophoretic transdermal system for the management of acute postoperative pain in hospitalized adults, and a paclitaxel-eluting cobalt ...
Updated Guidelines for Treatment of Ovarian Cancer Mar 27, 2006
Cancer Consultants (press release), ...the following chemotherapy regimens were added as treatment options: Gemzar® (gemcitabine)/Paraplatin® (carboplatin) and Paraplatin/Taxol® (paclitaxel). ...
Merck stands aside as Bayer scoops up Schering Mar 27, 2006
Pharma Times (subscription), Schering has an improved formulation of the widely-used cancer drug paclitaxel in late-stage clinical testing, as well as oral VEGF inhibitor PTK/ZK, also in ...
Abraxis Oncology Names Joseph Hogan Vice President of US Sales and ... Mar 20, 2006
Business Wire (press release), Hogan will be responsible for leading the US sales and marketing teams for ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound particles for ...
Study puts drug-eluting stents to test in heart attack patients Mar 13, 2006
EurekAlert (press release), The Randomized Comparison of Paclitaxel Eluting Stent Versus Conventional Stent in ST-segment Elevation Myocardial Infarction (PASSION) study has taken the ...
Excellent in-stent restenosis clinical trial results reported for ... Mar 12, 2006
Canada NewsWire (press release), ...restenosis) clinical trial(1). The results demonstrated that patients treated for in-stent restenosis with the TAXUS(R) Express2(TM) paclitaxel-eluting stent ...
Angiotech partner to release broad range of clinical study results ... Mar 7, 2006
PR Newswire (press release), BSC will release nine-month results from the TAXUS V In-Stent Restenosis (ISR) clinical trial, which evaluates the TAXUS Express2 paclitaxel-eluting coronary ...
Cell Therapeutics, Inc. CEO Talks About Lung Cancer Treatments for ... Mar 9, 2006
PharmaLive.com (press release), XYOTAX (paclitaxel poliglumex) is a biologically-enhanced chemotherapeutic that links paclitaxel, the active ingredient in Taxol(R), to a biodegradable ...
Concurrent Radiation Therapy and Chemotherapy for Small Cell Lung ... Mar 16, 2006
Cancer Consultants (press release), ...to an article recently published in the British Journal of Cancer, chemotherapy including Paraplatin® (carboplatin), Taxol® (paclitaxel), and Vepesid ...
Medtronic Sues Guidant In Ireland For Stent Patent Infringement ... Mar 28, 2006
Trading Markets, Medtronic alleged that the TAXUS® Paclitaxel-eluting coronary stent system infringes Medtronic's Fitzmaurice and Anderson patents. ...
JAMA Article Says TAXUS Stents Superior To Brachytherapy In ... Mar 15, 2006
Trading Markets, In the TAXUS Vs ISR (in-stent restenosis) clinical trial, it was found that TAXUS Express2 paclitaxel-eluting stent system was superior to radiation-based ...
Studies compare stents and cardiac procedures for long-term ... Mar 14, 2006
EurekAlert (press release), Richmond, used the pooled results of 15 independent head-to-head trials to compare the efficacy of sirolimus-eluting stents (SES) to paclitaxel-eluting stents ...
Examining stenting options in diabetics Mar 13, 2006
RxPG NEWS, Dr. Simonton and the STENT Group of eight coronary intervention centers have examined how the sirolimus-eluting (SES) and paclitaxel-eluting stents (PES ...
Boston Scientific files FDA application for new stent Mar 8, 2006
Reuters The medical device maker said it completed its premarket application for its Taxus Liberte paclitaxel-eluting coronary stent. The ...
Earnings: Microvision narrows loss in 4th quarter Mar 16, 2006
Seattle Post Intelligencer 81 cents per share, in 2004. Sonus said it is positioning its Tocosol Paclitaxel anti-cancer drug for approval and introduction.
Drug-Coated Stents Beat Radiation at Reopening Arteries Mar 12, 2006
Forbes ...companies that market coated stents -- Johnson & Johnson, whose stents are coated with sirolimus; and Boston Scientific, whose stents are coated with paclitaxel ...
UPDATE 1-Boston Scientific files FDA application for new stent Mar 8, 2006
Reuters The Natick, Massachusetts-based medical device maker said it completed a premarket application for its Taxus Liberte paclitaxel-eluting coronary stent. ...
Drug-coated stents work where older stents failed Mar 13, 2006
Reuters.uk, Two clinical studies indicate that inserting a stent covered with the drug paclitaxel or sirolimus inside the old clogged stent reduces the risk of the vessel ...
Boston Scientific Reports Excellent In-Stent Restenosis Clinical ... Mar 12, 2006
Trading Markets, ...from its TAXUS V ISR (in-stent restenosis) clinical trial showed that patients treated for in-stent restenosis with the TAXUS Express2 paclitaxel-eluting stent ...
Boston Scientific Submits PMA Application Final Module To FDA For ... Mar 8, 2006
Trading Markets, ...has submitted the final module of the Pre-Market Approval application to the US Food and Drug Administration for its TAXUS Liberte paclitaxel-eluting coronary ...
OXiGENE Completes Patient Enrollment In Clinical Trial Evaluating ... Mar 23, 2006
Trading Markets, ...of the triple combination of Combretastatin A4P (CA4P | charts | news | Powerrating) together with widely-used chemotherapy agents, carboplatin and paclitaxel. ...
Abdominal Chemo Boosts Survival In Ovarian Cancer Patients Mar 10, 2006
eMaxHealth.com, The benefits were overshadowed by the promise of new chemotherapy drugs such as paclitaxel, one of the chemo drugs used in Armstrong's study. ...
Pro-Pharmaceuticals' Abstract Accepted for Publication in ASCO ... Mar 17, 2006
International News Service, The Company has been conducting clinical and pre-clinical studies with 5-FU, leucovorin, irinotecan, doxorubicin, oxaliplatin, paclitaxel, cisplatin, and ...
Antisoma's Completes Enrollment in Ovarian Cancer Trial Mar 20, 2006
International News Service, The standard chemotherapy regime for these ovarian cancer patients is carboplatin and paclitaxel, the same as in the ongoing lung cancer study. ...
Drug-Releasing Stents More Effective Than Radiation Mar 13, 2006
Ivanhoe, The first study finds stents that release the drug paclitaxel to treat the narrowing within an implanted bare-metal stent prevent the risk of re-narrowing ...
US Advisers Against New Indication for Gemzar Mar 15, 2006
Cancerpage.com, Reuters) - Advisers to the US Food and Drug Administration recommended on Monday against approving Eli Lilly & Co.'s Gemzar (gemcitabine/paclitaxel) to treat ...
Es gibt keinen Besseren Mar 15, 2006
Finanzen.net, ...the safety and efficacy of the XIENCE V Everolimus ElutingCoronary Stent System compared to the TAXUS(R) Express 2(TM)Paclitaxel-Eluting Coronary Stent System ...
Drug-eluting stent beat radiation in study Mar 13, 2006
United Press International The nine-month study showed that patients treated with the Taxus stents -- which are coated with the drug paclitaxel -- reduced the need for additional artery ...
Stent Repair: Coated replacements better than radiation Mar 17, 2006
Science News Only 9 percent and 11 percent of stents laced with the drugs sirolimus (Rapamycin) and paclitaxel (Taxol), respectively, needed to be reopened during the two 9 ...
Oncologists Jumped Gun on Taxanes After Oral Presentation Mar 17, 2006
MedPage Today, The CALGB 9344 results reported in 1988 showed that adjuvant Taxol (paclitaxel) significantly improved survival for women with lymph-node-positive breast cancer ...
Phase III Non-Small Cell Lung Cancer Trial Studying Nexavar ... Feb 26, 2006
Medical News Today (press release), III clinical trial studying Nexavar® (sorafenib) tablets administered in combination with the chemotherapeutic agents carboplatin and paclitaxel in patients ...
Meeting Presentations Can Influence Treatment Patterns Mar 15, 2006
Medscape (subscription) ...with breast cancer who were diagnosed soon after a scientific presentation and widespread media coverage of the results from a trial of paclitaxel for early ...
Guidant Completes Enrollment in Randomized US Portion of Drug ... Mar 15, 2006
Business Wire (press release), ...evaluating the safety and efficacy of the XIENCE V Everolimus Eluting Coronary Stent System compared to the TAXUS(R) Express 2(TM) Paclitaxel-Eluting Coronary ...
Concurrent Radiation Therapy and Chemotherapy for Small Cell Lung ... Mar 16, 2006
Cancer Consultants (press release), ...with limited small cell lung cancer (SCLC) following concurrent radiotherapy and chemotherapy with Paraplatin® (carboplatin), Taxol® (paclitaxel) and Vepesid ...
Taxotere®/Platinol®/Herceptin® Effective in Locally Advanced ... Mar 22, 2006
Cancer Consultants (press release), Herceptin is currently approved for the treatment of HER2-positive, metastatic breast cancer with the chemotherapy agent Taxol® (paclitaxel), or as a single ...
Angiotech partner submits final module for TAXUS(R) Liberte(TM) ... Mar 8, 2006
Yahoo! News (press release) US Food and Drug Administration (FDA) the final module of BSC's Pre-Market Approval (PMA) application for its TAXUS® Liberte(TM) paclitaxel-eluting coronary ...
SD Pharma wraps up pre-clinical studies Mar 24, 2006
San Diego Daily Transcript (subscription), ...(News) in Carlsbad announced Friday that it has completed a battery of pre-clinical studies on its novel nano-emulsion formulation of paclitaxel, a formulation ...
Taxol® and Paraplatin® Superior to Novantrone® for Hormone ... Mar 10, 2006
Cancer Consultants (press release), According to an article recently published in the journal Urology, treatment consisting of Taxol® (paclitaxel) and Paraplatin® (carboplatin) provides ...
Conor Medsystems Licenses Compound from Novartis for Development ... Mar 16, 2006
PharmaLive.com (press release), One stent will be loaded with pimecrolimus, and the other stent will be a dual-drug stent loaded with both pimecrolimus and paclitaxel. ...
At the Crossroads of Medicine and Money Feb 26, 2006
Los Angeles Times, It wraps one of the best-known cancer fighters — paclitaxel, a compound derived from the Pacific yew — inside particles of a blood protein thousands of ...
Angiotech shares up on Taxus registry data Mar 14, 2006
BusinessWeek Boston Scientific, based in Natick, Mass., bought worldwide exclusive rights from Vancouver, British Columbia-based Angiotech to use paclitaxel to coat its ...
Angiotech Shares Up on Taxus Registry Data Mar 14, 2006
Houston Chronicle, Boston Scientific, based in Natick, Mass., bought worldwide exclusive rights from Angiotech to use paclitaxel to coat its coronary stent products and has co ...
Early, Unproven Findings Changing Doctors' Practice Mar 14, 2006
Forbes In the JNCI study, Giordano's group tracked changes in breast-cancer treatment after researchers announced preliminary findings on Taxol (paclitaxel) at the ...
Taxus holds market share Mar 14, 2006
Pioneer Press, ...force, Kucheman said. Barracuda stents will be coated initially with the same drug as the Taxus, paclitaxel. Eventually, the product ...
STENT Registry Safety Data Favors TAXUS Over Cypher In The Most ... Mar 12, 2006
Trading Markets, The study included follow-up on 5,566 patients at eight coronary centers in the United States who received either a TAXUS Express2 paclitaxel-eluting coronary ...
ACC: Taxus Stent Beats Radiation for Treating InStent Restenosis Mar 12, 2006
MedPage Today, ATLANTA, March 12 - Putting the Taxus Taxol (paclitaxel)-eluting stent within a failed bare-metal stent beats vascular brachytherapy at preventing restenosis ...
Boston Scientific Submits Final Module Of Its Pre-Market Approval ... Mar 8, 2006
Trading Markets, ...it has submitted the final module of its Pre-Market Approval (PMA | charts | news | Powerrating) application for its TAXUS Liberte paclitaxel-eluting coronary ...
Dose-Dense Chemotherapy Safe and Effective; Particularly for ... 21 Dec 2005
Cancer Consultants (press release), Patients received the study drugs Adriamycin® (doxorubicin), Taxol® (paclitaxel), and Cytoxan® (cyclophosphamide), either concurrently, or sequentially in ...
Integrated BioPharma Announces the Appointment of General Hill as ... 21 Dec 2005
PR Newswire (press release), Its pharmaceutical business operates a cGMP facility for the production and sale of Paclitaxel and related drugs and provides technical services through its ...
American Bioscience Inc. Names Barry Flannelly, Pharm.D, MBA, as ... 21 Dec 2005
PR Newswire (press release), ...entirely to developing and promoting innovative, next-generation cancer therapies such as ABRAXANE(R) for Injectable Suspension (paclitaxel protein-bound ...
GPC Biotech Submits CMC Section Of Satraplatin NDA 21 Dec 2005
BioWorld Online (subscription), ...satraplatin include a Phase II monotherapy trial among metastatic breast cancer patients, a Phase II combination trial with Taxol (paclitaxel) for inoperable ...
Herceptin, new breast cancer medication 21 Dec 2005
Auburn Citizen, The FDA has approved Herceptin as a first line use with paclitaxel, a class of chemotherapy drugs that prevent cancer cell division and promote cancer cell ...
Little Difference between Docetaxel and Paclitaxel in Treating ... Dec 14, 2005
DG News ...is virtually no difference in disease-free survival when a regimen comprising doxorubicin and cyclophosphamide is followed by either docetaxel or paclitaxel. ...
Paclitaxel, docetaxel show similar breast cancer benefit Dec 9, 2005
myDNA.com, Results from a clinical trial comparing the effectiveness of the drugs paclitaxel and docetaxel, delivered over two different dosing schedules, showed that ...
Bioxel Wins Paclitaxel Purchase Agreement With A New European ... Dec 9, 2005
CCNMatthews (Communiqués de presse), Bioxel's client is already marketing its generic paclitaxel formulation in several EU countries and intends to obtain approvals throughout Europe in 2006. ...
Sonus Pharmaceuticals to Present TOCOSOL(R) Paclitaxel Clinical ... Dec 2, 2005
Business Wire (press release), 2, 2005--Sonus Pharmaceuticals, Inc. (NASDAQ:SNUS) today announced the scheduled presentation of a poster on TOCOSOL(R) Paclitaxel at the upcoming San Antonio ...
Some stents may cause allergic reactions Dec 19, 2005
Science Daily (press release) Study: Paclitaxel stents more effective (September 13, 2005) -- Researchers say stents that release the medication paclitaxel reduce the risk of an artery re ...
Sonus Pharmaceuticals Presents Encouraging Phase 2 Efficacy and ... Dec 8, 2005
PharmaLive.com (press release), ...(Nasdaq: SNUS) today presented encouraging safety and efficacy data from the Phase 2 clinical program for TOCOSOL(R) Paclitaxel at the San Antonio Breast ...
Sonus Pharmaceuticals to Present TOCOSOL Paclitaxel Clinical Data ... Dec 2, 2005
PharmaLive.com (press release), ...(NASDAQ:SNUS) today announced the scheduled presentation of a poster on TOCOSOL(R) Paclitaxel at the upcoming San Antonio Breast Cancer Symposium, to be held ...
Pilot Study Shows Abraxane Safe and Effective in Sequence with ... Dec 13, 2005
DG News SAN ANTONIO, TX -- December 13, 2005 -- A novel form of paclitaxel, encapsulated in albumin, could represent the first drug designed to treat breast cancer ...
Two Types of Breast Cancer Treatments Show Similar Benefit Dec 9, 2005
PharmaLive.com (press release), WASHINGTON, December 8, 2005-Results from a clinical trial comparing the effectiveness of the drugs paclitaxel and docetaxel, delivered over two different ...
*vwd/BUSINESS WIRE: SMT steigt in die erste Liga der Hersteller ... Dec 15, 2005
Vereinigte Wirtschaftsdienste, SMT hat für einen ihrer führenden mit Medikamenten beschichteten Stents, das "Infinnium(TM) Paclitaxel System", die Zulassung vom Medicine Evaluation Board ...
SMT joins Big League of Drug Eluting Stent Manufacturers Dec 15, 2005
Business Wire (press release), ...the European Community's Medicine Evaluation Board (MEB) in the Netherlands -- for one of their lead drug eluting stents, the "Infinnium(TM) Paclitaxel System ...
Symptoms and signs of an acute myocardial ischemia caused by ... Dec 16, 2005
HeartZine, Introduction: Paclitaxel (Taxol) is an anticancer agent used for the treatment of breast and ovarian cancer. The major side effects ...
Xechem Settles Antitrust Lawsuit Against Bristol-Meyers Squibb for ... Dec 20, 2005
Genetic Engineering News, ...that Bristol-Meyers had engaged in anticompetitive practices relating to Xechem's efforts to manufacture and bring to market the drug paclitaxel, a generic ...
Pivotal Trial to Evaluate Comparative Effectiveness of XYOTAX to ... Dec 6, 2005
PharmaLive.com (press release), ...(CTI) today announced plans to initiate a clinical trial in women of XYOTAX (paclitaxel poliglumex) versus paclitaxel chemotherapy for the treatment of PS2 ...
Pivotal Trial to Evaluate Comparative Effectiveness of XYOTAX(TM) ... Dec 6, 2005
PR Newswire (press release), ...(CTI) (Nasdaq and MTAX: CTIC) today announced plans to initiate a clinical trial in women of XYOTAX (paclitaxel poliglumex) versus paclitaxel chemotherapy for ...
Bioxel Pharma Announces Results for the Third Quarter of 2005 Nov 23, 2005
CCNMatthews (Communiqués de presse), European generic market, we have significantly reduced our production costs and we have broadened our taxanes product line to paclitaxel and docetaxel ...
Mayo Clinic Reports Tamoxifen Benefit For Breast-cancer Patients ... Dec 19, 2005
Science Daily (press release) ...metastatic breast cancer. The researchers tested a combination of two drugs -- paclitaxel and ... > full story. Raloxifene After ...
Mayo Clinic Discovers Two Key Players In Cancer Prevention And How ... Dec 19, 2005
Science Daily (press release) ...metastatic breast cancer. The researchers tested a combination of two drugs -- paclitaxel and ... > full story. Mayo Clinic Cancer ...
C-myc Gene Influences Response to Herceptin® Dec 14, 2005
Cancer Consultants (press release), The researchers evaluated patients in the NSABP B-31 clinical trial, which compared treatment with AC-T (doxorubicin,cyclophosphamide,paclitaxel) to treatment ... |
